Metsera is a hot commodity in the obesity drug market, with Novo Nordisk and Pfizer in a bidding war for access to its pipeline of experimental treatments. Their lead candidate, MET-097i, boasts promising results, helping patients lose up to 14.1% of their body weight in a mid-stage study. Metsera has attracted deep-pocketed backers like Alphabet and has seen its shares double since its market debut. The bidding war may signal a new phase in the obesity drug race, with companies like Viking Therapeutics and Structure Therapeutics also seeing a boost in their shares as investors seek the next breakout in the market.

Read more at Yahoo Finance: Metsera the US obesity biotech at centre of Novo, Pfizer bidding war